Efficacy and Safety of S18986 in the Treatment of Mild Cognitive Impairment Patients

Efficacy of 15 mg and 50 mg of S18986 on Cognitive Symptoms in Mild Cognitive Impairment Patients Treated Over a 12-month Oral Administration Period

Status

Terminated

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00202540

Enrollment

Registered

2005-09-20

Start date

2005-06-30

Completion date

2006-03-29

Last updated

2024-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mild Cognitive Impairment

Brief summary

The purpose of this study is to demonstrate a long term efficacy of S18986 versus placebo on episodic memory performance in patients with MCI

Interventions

DRUGS18986

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

55 Years to No maximum

Healthy volunteers

Inclusion criteria

* Memory complaint * Acetylcholinesterase inhibitors stopped at least 3 months before selection

Exclusion criteria

* Dementia * Parkinson's disease * Vascular disorder * Depression * Epilepsy

Design outcomes

Primary

Measure	Time frame
Episodic memory	—

Secondary

Measure	Time frame
Other cognitive domains, activities of daily living, global impression of change, MRI, safety.	—

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026